BCL7A

Across TCGA pan-cancer cohorts, BCL7A mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of BCL7A’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where BCL7A mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types BCL7A is over-expressed in tumor, although a few such as CCRCC and PDAC show the opposite, repressed pattern.

CCRCC, PDAC, and HNSC are the cancer types where BCL7A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BCL7A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	IV	−0.790	<.001	11	view →
PDAC	Female	II,III,IV	−0.986	<.001	8	view →
HNSC	Male	All	+0.421	<.001	8	view →
LSCC	Male	All	+0.645	<.001	7	view →
LUAD	Female	II,III,IV	+0.411	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

BCL7A–CCRCC

Open the CCRCC breakdown →